Closed
Source verified April 27, 2026
FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award
Translational funding for Angelman syndrome research
Latest source updateLast Update: May 10, 2026Latest change: The IMPACT Award page now presents a fuller policies document with updated submission guidance, added review rules, and clearer application requirements.View change
Latest source update
Last Update: May 10, 2026
Latest change: The IMPACT Award page now presents a fuller policies document with updated submission guidance, added review rules, and clearer application requirements.
FAST IMPACT award policies updated
The IMPACT Award content has been expanded into a detailed policies document that adds new sections on key dates, similar applications, human and animal subjects, grant review, no-cost extensions, carry-forward, and nondiscrimination. It also updates application instructions, including the LOI and submission email, PDF-only review, and a more explicit required-outline structure. The core award purpose and funding level remain centered on translational Angelman syndrome research up to the IND-enabling stage, but the process and compliance requirements are now much more fully specified.
Funding available
$ 1,000,000
Deadline
Open continuously
Location
Canada
Overview
Supports translational Angelman syndrome research toward clinical trials. Funding is up to $1,000,000 per year for innovative, high-impact studies and IND-enabling work.
/100
Opportunity Score
Moderate potential, but conditions must align.
At a glance
Funding available
Financing goals
- Develop a new program or service
- Enhance an existing program
- Conduct research and development activities
Eligible Funding
- Maximum amount : 1,000,000 $
Funds Providers
Eligible candidates
Eligible Industries
- All industries
Location
- Canada
Legal structures
- Non-profit
Annual revenue
- All revenue ranges
Organisation size
- All organization sizes
Audience
- All groups
Non-profit candidates
Sector of operation
- Research
Target groups
- Nonprofits / charities
- Academia / students
Revenue structures
- 100% donations / grants
Scope
- National
- International
Next Steps
1
Determine your project
2
Validate your eligibility
Activities funded
- Translational research platform projects for Angelman syndrome
- Pre-clinical studies advancing toward IND-enabling work
- Studies of pharmacological, biologic, gene-editing, or gene-replacement therapies
- Repurposing of approved or clinically safe therapies for Angelman syndrome
Documents Needed
- Letter of Intent
- Research plan
- Budget and budget justification
- CV or NIH biosketch
- Other support information
Official resources
Application form
Eligibility
Who is eligible?
- Nonprofit research institutions
- Academic investigators
- Scientists and clinicians with PhD- or MD-level training
Who is not eligible
- For-profit institutions
- Applicants without PhD- or MD-level training and experience
Eligible expenses
- Reagents and research materials
- External research services
- Specialized equipment or software
- Personnel salaries and fringe benefits
- Travel to the FAST scientific symposium
Ineligible Costs and Activities
- Indirect costs on tuition, equipment, software, or software licenses
- Applications with the same research focus from the same applicant organization on the same submission date
Selection criteria
- Scientific merit
- Innovation
- Translational impact
- Alignment with FAST’s mission
- Feasibility and experimental design
How to apply
- Step 1: Submit Letter of Intent
- Send an LOI to FAST before applying.
- Include the project summary, budget estimate, duration, preliminary data, and CV or biosketch.
- Step 2: Prepare the application package
- Complete the FAST application form and research plan.
- Include the budget, budget justification, other support, facilities, and biosketch documents.
- Step 3: Submit electronically
- Upload the application through the electronic submission link.
- Submit the materials as PDF files.
Processing and Agreement
- Applications are first reviewed by the Scientific Advisory Board.
- Applications are scored for scientific merit, innovation, translational impact, and mission alignment.
- Recommendations are reviewed by the Scientific Director Panel.
- Final approval is made by the FAST Board of Directors.
- Applicants may need to respond to SAB questions or recommendations before a final decision.
Additional information
- Applications are accepted on a rolling basis.
- A Letter of Intent is required before applying.
- Projects longer than one year require annual renewal.
Contacts
Frequently Asked Questions about the FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award Program
What is the FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award?
Supports translational Angelman syndrome research toward clinical trials. Funding is up to $1,000,000 per year for innovative, high-impact studies and IND-enabling work.
How much funding can be received?
FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award Funds up to $1,000,000 of admissible expenses.
Who is eligible for the FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award program?
To be eligible for the FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award program, you must:
Nonprofit institution required.
PhD- or MD-level applicant.
Full-time research commitment.
What expenses are eligible under FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award?
Translational research platform projects for Angelman syndrome
Pre-clinical studies advancing toward IND-enabling work
Studies of pharmacological, biologic, gene-editing, or gene-replacement therapies
Repurposing of approved or clinically safe therapies for Angelman syndrome
Who can I contact for more information about the FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award?
You can contact Foundation for Angelman Syndrome Therapeutics (FAST) by email at science@cureangelman.org or by phone at 630-852-3278.
Where is the FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award available?
The FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award program is available across Canada.
Is the FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award a grant, loan, or tax credit?
FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award is a Researchers And Facilities